Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Amoeba SA ( (FR:ALMIB) ).
Amoéba SA has made significant strides in 2024, achieving key milestones that position it closer to commercializing its biocontrol product, AXPERA, by late 2025 or early 2026. The company signed a Memorandum of Understanding with Koppert for potential collaboration and received positive regulatory feedback from the EFSA, enhancing its market readiness. Additionally, Amoéba advanced its cosmetic ingredient development, securing INCI listing and Cosmos certification, which facilitates market entry. These developments, along with improved financial results and expanded production capacity, underscore Amoéba’s strategic shift towards industrialization and commercialization, promising potential growth and impact in the biocontrol and cosmetics industries.
More about Amoeba SA
Amoéba SA is an industrial greentech company based in Chassieu, France, specializing in the development of natural microbiological solutions using patented amoebae technology. The company focuses on biocontrol products for agriculture and cosmetic ingredients, aiming to provide sustainable and effective alternatives in these markets.
YTD Price Performance: 10.11%
Average Trading Volume: 2,454
Technical Sentiment Signal: Hold
Current Market Cap: €54.13M
For a thorough assessment of ALMIB stock, go to TipRanks’ Stock Analysis page.